A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Inclusion Criteria: * All subjects: * Male and female subjects aged 18-75 years. * Body weight at least 55 kg with a body mass index between 18-35 kg/m2. * Hepatic impairment subjects: * Mild or moderate hepatic impairment. Exclusion Criteria: * All subjects: * Clinical manifestations of postural symptomatic hypotension at screening or baseline. * History of hypersensitivity to LCZ696 or to drugs of similar classes. * Hepatic impairment subjects: * Hepatic impairment due to non-liver disease. * Treatment with any vasodilator, autonomic alpha blocker or beta2 agonist within 2 weeks of dosing. * Encephalopathyy Stage III or IV. * Primary biliary liver cirrhosis or biliary obstruction. * History of gastro-intestinal bleeding within 3 months prior to screening. * Healthy subjects: * Any surgical or medical condition which might significantly alter the distribution, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. * Use of prescription drugs, herbal supplements, and/or over-the-counter medication, dietary supplements (vitamins included) within 2 weeks prior to initial dosing. Other protocol-defined inclusion/exclusion criteria may apply.